Combined Immunodeficiency Due to ORAI1 Deficiency

Combined immunodeficiency due to ORAI1 deficiency is an ultra-rare genetic immune disorder where the body cannot move calcium properly into immune cells after they are activated. This problem comes from harmful (pathogenic) changes in the ORAI1 gene, which codes for a key part of the “CRAC” calcium channel (calcium-release activated calcium channel). As a result, T cells and other immune cells are present in normal numbers, but they cannot switch on and work properly. Children develop severe, repeated infections, muscle weakness (myopathy), and features of ectodermal dysplasia such as poor tooth enamel and inability to sweat (anhidrosis). Without strong specialist care, many affected children can become critically ill early in life.[1][2]

Combined immunodeficiency due to ORAI1 deficiency is an ultra-rare inherited immune system disease. In this condition, a gene called ORAI1 does not work properly. ORAI1 normally forms part of a special calcium channel (called a CRAC channel) on immune cells. When this channel is damaged, immune cells cannot get enough calcium signals. Because of this, T cells, B cells and other white blood cells cannot switch on and fight germs in a normal way. Children usually develop severe or repeated infections early in life, along with weak muscles and skin, hair, teeth and sweat-gland problems (ectodermal dysplasia).

Pathophysiology

In healthy people, the ORAI1 protein sits in the surface of the cell and forms the pore of the CRAC channel. When the endoplasmic reticulum (a calcium store inside the cell) runs low, another protein called STIM1 senses this and signals ORAI1 to open, so calcium flows into the cell. This flow is essential for T-cell activation, cytokine production, muscle contraction, and sweat gland function.[3]

In ORAI1 deficiency, both copies of the ORAI1 gene usually carry loss-of-function variants. The CRAC channel does not open properly, so store-operated calcium entry is almost absent. T cells and other lymphocytes develop in normal numbers, but they cannot fully activate, divide, or kill infected cells. This leads to combined immunodeficiency with severe viral, bacterial, and fungal infections. The same calcium problem affects muscle cells and sweat glands, causing congenital myopathy, weak muscle tone (hypotonia), enamel defects, and anhidrotic ectodermal dysplasia.[1][2][4]

Because this condition is so rare, information comes mainly from case reports and small series. However, nearly all reports describe early-onset severe infections, poor infection control with standard treatment, and high risk of early death without hematopoietic stem cell transplantation (HSCT).[5][6]

Other names and types

Doctors and researchers use several other names for the same condition. These names all describe the same basic disease: a serious immune deficiency caused by faulty calcium entry into immune cells. Common synonyms include:

• Immunodeficiency-9 (IMD9)

• Immune dysfunction with T-cell inactivation due to calcium entry defect 1

• CID due to ORAI1 deficiency

• Combined immunodeficiency due to CRAC channel dysfunction
  These names may appear in medical reports, genetic test results or research papers, but they all point to the same ORAI1-related combined immunodeficiency.

There is only one main disease, but doctors sometimes describe clinical patterns (types) based on how strong the gene defect is and which symptoms are seen:

• Type 1 – Classic severe ORAI1 deficiency: children have complete loss of ORAI1 function, very poor T-cell activation, frequent severe infections, marked muscle weakness and clear ectodermal dysplasia (abnormal teeth, hair and sweating).

• Type 2 – Partial (hypomorphic) ORAI1 deficiency: gene changes reduce, but do not totally remove, channel function. Infections and muscle problems may be slightly milder or appear later, but immune function is still clearly impaired.

• Type 3 – CRAC channelopathy with mixed loss- and gain-of-function variants: very rare patients may have unusual ORAI1 changes that partly block and partly over-activate calcium entry, leading to a mixed picture of immunodeficiency plus immune dysregulation or other organ problems.

Causes

The main cause of this disease is always a harmful change (mutation) in both copies of the ORAI1 gene. Below are 20 related “causes” and mechanisms that explain how and why the disease appears and how it behaves in the body.

1. Autosomal recessive ORAI1 gene mutation
The basic cause is an autosomal recessive mutation in the ORAI1 gene. A child must receive one faulty copy from each parent. When both copies are mutated, ORAI1 protein cannot work properly, and the CRAC calcium channel in immune cells fails.

2. Loss-of-function (LoF) mutations in ORAI1
Most patients carry “loss-of-function” mutations. These changes either stop ORAI1 from being made at all or produce a protein that cannot form a working channel. Without proper ORAI1, store-operated calcium entry (SOCE) is almost absent in T cells, so they cannot activate normally against infections.

3. Null (truncating) ORAI1 mutations
Some patients have frameshift or nonsense mutations that create a very short ORAI1 protein. The cell usually destroys these short proteins. This results in a complete lack of ORAI1 on the cell surface and a total block of CRAC channel function, causing very severe immunodeficiency.

4. Missense mutations that distort the channel pore
Other patients have missense mutations (single amino-acid changes), such as the well-known R91W variant, that leave the protein present but block calcium flow through the pore. The channel looks normal but cannot conduct calcium, which still gives a strong combined immunodeficiency picture.

5. Compound-heterozygous ORAI1 mutations
In some families, the patient inherits two different harmful mutations in ORAI1 (one from each parent). This is called compound heterozygosity. Even though the two copies are not identical, both are faulty, so there is still no normal ORAI1 protein and the same disease develops.

6. Abolished store-operated calcium entry (SOCE)
All these mutations share one central effect: they abolish or severely reduce SOCE. Without this calcium entry pathway, immune cells cannot increase their intracellular calcium after receptor stimulation, which is essential for turning on many genes required for immune responses.

7. Defective T-cell activation
T cells need calcium signals through ORAI1 to become activated, divide and produce cytokines. In ORAI1 deficiency, T cells are present but respond very poorly to stimulation, so they cannot coordinate the immune response against viruses, bacteria and fungi.

8. Impaired B-cell help and antibody production
Because T cells do not work well, they cannot help B cells to make strong, specific antibodies. Patients may have normal or even high immunoglobulin levels in the blood, but these antibodies are often ineffective, and vaccine responses are weak or absent.

9. Abnormal natural killer (NK) cell and γδ T-cell function
Studies show altered composition and function of NK cells and γδ T cells in ORAI1 deficiency. These cells are also involved in early defence against viruses and some bacteria. Their dysfunction further increases the risk of severe and unusual infections.

10. Congenital myopathy due to ORAI1 defects in muscle
ORAI1 is expressed in skeletal muscle. When it is absent or defective, calcium handling in muscle cells is disturbed. This leads to congenital, non-progressive muscle weakness (myopathy) and low muscle tone (hypotonia), which are key parts of the disease.

11. Ectodermal dysplasia from faulty calcium signalling in skin and teeth
ORAI1 is also important in cells that form enamel, sweat glands and other ectoderm-derived tissues. When ORAI1 is missing, enamel becomes thin and soft, sweat glands may not work (anhidrosis), and hair and skin may be abnormal, giving an ectodermal dysplasia picture.

12. Increased susceptibility to a wide range of pathogens
Because several types of immune cells are affected, patients become vulnerable to many organisms: bacteria (such as Streptococcus pneumoniae), herpes viruses, atypical mycobacteria and fungi like Candida. These repeated infections are not separate causes but are direct results of the underlying ORAI1 defect.

13. Autoimmune complications from faulty immune regulation
CRAC channel defects can disturb the balance between effector cells and regulatory T cells. This may contribute to autoimmune problems, such as autoimmune anaemia or low platelets, which are sometimes seen in CRAC channelopathies.

14. Parental consanguinity (related parents)
When parents are blood relatives, they are more likely to carry the same rare ORAI1 mutation. This increases the chance that a child will inherit two faulty copies and develop the disease. Consanguinity itself does not cause the mutation but raises the risk that recessive diseases like this will appear.

15. Positive family history of early severe infections or known ORAI1 mutation
Families with previous siblings who had severe early-onset infections, muscle weakness and ectodermal problems may carry ORAI1 mutations. A known family mutation is an important causal clue and explains why more than one child can be affected.

16. De novo (new) ORAI1 mutations
In rare cases, an ORAI1 mutation may appear for the first time in a child, even when parents are not carriers. This “de novo” mutation still disrupts the channel and causes the same immunodeficiency, though it is less common than inherited mutations.

17. Mixed loss- and gain-of-function mutations in ORAI1
Recent reports describe patients with ORAI1 changes that partly reduce normal activation but also cause some constant calcium entry. These mixed-effect mutations still produce immunodeficiency, because the timing and size of calcium signals become abnormal and immune cells cannot respond correctly.

18. Disruption of ORAI1–STIM1 signalling complex
ORAI1 works together with another protein, STIM1, to sense calcium in the endoplasmic reticulum and open the CRAC channel. ORAI1 mutations disturb this partnership. Even if STIM1 is normal, the complex fails, and calcium entry is lost, driving the immunodeficiency.

19. Wider CRAC channelopathy affecting multiple organs
ORAI1 deficiency is part of a broader group called “CRAC channelopathies”. In these disorders, calcium entry problems affect not only immune cells but also muscle, skin and other tissues. This explains why patients have both immunodeficiency and non-immune features, and it reflects a systemic cause.

20. Environmental exposure unmasked by ORAI1 deficiency
Normal children can usually control common viruses and bacteria. In ORAI1-deficient children, the same everyday exposures can cause severe disease because their immune system cannot respond well. The environment does not cause the gene problem, but it strongly influences how often and how severely symptoms appear.

Symptoms

1. Recurrent and severe infections
The most important symptom is repeated, often serious infections starting in early infancy. These can include pneumonia, sepsis, chronic ear infections, skin infections and persistent thrush. Infections are often caused by common viruses, bacteria, mycobacteria and fungi that a normal immune system would usually control.

2. Early onset of symptoms in newborns or infants
Many children show problems soon after birth or in the first months of life. Parents may notice that the baby is “always sick”, does not recover fully between infections, or needs frequent hospital stays for intravenous antibiotics.

3. Chronic or recurrent pneumonia
Repeated chest infections, especially pneumonia, are common. Children may have cough, fast breathing, chest retractions, low oxygen and need for hospital care. Over time, these infections can damage lung tissue and cause long-term breathing problems.

4. Chronic diarrhoea and gut infections
Some patients have long-lasting diarrhoea due to infections or immune problems in the gut. This can lead to dehydration, poor nutrient absorption and weight loss. Chronic diarrhoea is a warning sign of significant immune deficiency.

5. Failure to thrive and poor growth
Because of repeated infections, poor appetite and diarrhoea, many children fail to gain weight and height normally. Growth curves often show the child falling below expected percentiles, and they may look thin or small for their age.

6. Global muscular hypotonia (floppy muscles)
A very typical feature is “floppy” muscles. Babies may have poor head control, feel limp when lifted, and be late in rolling, sitting or walking. This reflects congenital myopathy caused by ORAI1 deficiency in skeletal muscle.

7. Reduced muscle strength and endurance
Older children may walk but tire quickly, have difficulty climbing stairs or standing from the floor, and may show a Gowers’ sign (pushing on their thighs to stand up). The weakness is usually non-progressive but clearly limits daily activities.

8. Ectodermal dysplasia of teeth (soft or thin enamel)
Many patients have teeth with thin, soft enamel that wears down easily. Teeth may appear small, discoloured or prone to cavities. This reflects the role of ORAI1 in enamel-forming cells (ameloblasts).

9. Reduced or absent sweating (anhidrosis)
Sweat glands in ectodermal dysplasia may not work normally. Patients may sweat very little or not at all. This can cause overheating, flushing and difficulty tolerating hot weather or fever.

10. Abnormal hair and skin
Some children have sparse scalp hair, dry or scaly skin and eczema-like rashes. These changes are part of the ectodermal dysplasia and can be early external clues to an underlying CRAC channelopathy.

11. Oral ulcers and mouth problems
Recurrent aphthous ulcers and chronic oral thrush may occur because of poor local immune defence and altered mucosal health. These make eating uncomfortable and can worsen nutrition.

12. Lymphadenopathy and hepatosplenomegaly
Some patients develop enlarged lymph nodes, liver and spleen. This can result from chronic infections, persistent immune activation or secondary conditions such as autoimmune reactions.

13. Autoimmune cytopenias
Autoimmune destruction of blood cells (for example, autoimmune haemolytic anaemia or immune thrombocytopenia) may occur in some CRAC channelopathy patients. This reflects disturbed immune regulation rather than infection itself.

14. Increased risk of severe viral infections
Children may develop serious disease from common viruses such as cytomegalovirus (CMV) or herpes viruses. These infections may be prolonged, widespread or unusually severe, because virus-specific T-cell responses are very weak.

15. Reduced quality of life and repeated hospitalisations
Because of frequent infections, weakness and hospital stays, children and families face many physical, emotional and financial stresses. School or social activities may be interrupted, and long-term care from immunology and other specialists is usually required.

Diagnostic tests

Doctors use a step-by-step set of tests to diagnose combined immunodeficiency due to ORAI1 deficiency. These tests check the clinical picture, basic immune function, calcium signalling and the ORAI1 gene itself.

Physical examination (examples of tests done during clinical exam)

1. General physical examination with growth assessment
The doctor examines the child’s overall appearance, measures weight, height and head size, and checks vital signs. Poor growth, recurrent infections, breathlessness or signs of chronic illness raise suspicion of a serious immune problem.

2. Skin, hair, teeth and nail inspection
Careful inspection may show dry skin, sparse hair, abnormal nails and teeth with thin enamel. These ectodermal dysplasia features, together with infections, suggest a CRAC channelopathy such as ORAI1 deficiency rather than a “pure” SCID.

3. Neuromuscular examination
The doctor evaluates muscle tone, reflexes, strength and coordination. Findings like “floppy” muscles, delayed motor milestones and reduced strength point towards congenital myopathy, a typical sign of ORAI1 deficiency.

4. Temperature regulation and sweating assessment
Clinicians may ask about heat intolerance and examine sweating patterns. Lack of sweating in hot conditions or during fever supports anhidrosis, again hinting at ectodermal dysplasia linked to ORAI1/CRAC channel disease.

Manual and bedside tests

5. Manual muscle strength grading
Using simple scales like the Medical Research Council (MRC) grading, the doctor manually tests strength in different muscle groups. Consistently reduced strength without clear progression supports a congenital myopathy rather than a degenerative muscle disease.

6. Developmental milestone assessment
Clinicians compare the child’s motor and social milestones (such as rolling, sitting, walking and speech) with standard charts. Delayed motor milestones in the context of infections and ectodermal changes raise suspicion for ORAI1-related disease.

7. Detailed family history and pedigree charting
Drawing a family tree and recording any relatives with early deaths, severe infections or known immunodeficiency helps identify autosomal recessive patterns. This manual evaluation guides genetic testing and counselling.

Laboratory and pathological tests

8. Complete blood count (CBC) with differential
A CBC checks levels of red cells, white cells and platelets. In ORAI1 deficiency, total lymphocyte numbers may be normal, unlike some classic SCID forms, but signs of infection (high neutrophils) or anaemia may be present. This helps distinguish CRAC channelopathy from other immunodeficiencies.

9. Serum immunoglobulin levels (IgG, IgA, IgM, IgE)
Blood tests measure total antibody levels. In ORAI1 deficiency, immunoglobulin levels can be normal or high, which is different from many antibody deficiency conditions. This pattern, combined with poor specific antibody responses, supports the diagnosis.

10. Specific antibody response testing (vaccine titres)
Doctors measure antibody levels against previous vaccines (such as tetanus or pneumococcus) or give controlled boosters and re-test later. Patients with ORAI1 deficiency often fail to produce good specific responses, showing that antibody function, not just quantity, is impaired.

11. Lymphocyte subset analysis by flow cytometry
This test counts different types of lymphocytes (T cells, B cells and NK cells) and looks at their markers. In ORAI1 deficiency, numbers of these cells are often near normal, but detailed patterns (for example, altered regulatory T cells) may suggest a CRAC channelopathy.

12. T-cell proliferation assays
T cells from the patient are stimulated in the lab with mitogens or specific antigens. In ORAI1 deficiency, proliferation is very poor because calcium-dependent signalling pathways cannot activate. This test confirms a major functional problem in T cells.

13. Store-operated calcium entry (SOCE) / calcium flux studies
Specialised laboratories can measure calcium entry into lymphocytes after internal calcium stores are emptied. In ORAI1 deficiency, SOCE is almost absent. This is a direct functional proof that the CRAC channel pathway is disrupted.

14. Targeted ORAI1 gene sequencing
Genetic testing of the ORAI1 gene is the definitive diagnostic test. Sequencing identifies missense, nonsense, frameshift or other mutations. Finding two disease-causing mutations (one on each copy) confirms combined immunodeficiency due to ORAI1 deficiency.

15. Next-generation sequencing immunodeficiency panels
In many centres, doctors order a broader primary immunodeficiency gene panel, which includes ORAI1 and many other genes. This is helpful when the exact cause is not clear. If ORAI1 mutations are found, they can then be confirmed and interpreted.

16. Muscle biopsy (when needed)
If the muscle problem is unclear, a biopsy may be done. In ORAI1-related disease, biopsy can show non-progressive myopathic changes or tubular aggregates, supporting a systemic channelopathy rather than a primary muscular dystrophy.

Electrodiagnostic tests

17. Electromyography (EMG)
EMG studies help distinguish myopathy (muscle disease) from neuropathy (nerve disease). In ORAI1 deficiency, results usually support a congenital myopathy pattern. This supports the idea that the same genetic problem affects both immune cells and muscle.

18. Nerve conduction studies (NCS)
NCS check how well nerves carry electrical signals. In most ORAI1-deficient patients, nerve conduction is relatively normal, which helps rule out primary peripheral neuropathy and points more to muscle-based weakness.

Imaging tests

19. Chest X-ray or chest CT scan
Imaging of the chest is important in children with recurrent pneumonia. It can show lung infections, scarring, bronchiectasis or structural problems. These findings do not prove ORAI1 deficiency but show the damage caused by repeated infections and guide supportive treatment.

20. MRI of brain and/or muscles
MRI may be used to rule out other causes of hypotonia or weakness and to look at muscle structure. It can help distinguish congenital myopathies from central nervous system causes and support a diagnosis of a systemic disorder like CRAC channelopathy.

Non-pharmacological treatments

1. Strict infection-control and hand hygiene

Daily infection-control measures are one of the most powerful “non-drug” treatments. Families are taught careful hand washing, use of alcohol-based hand rubs, cough etiquette, and keeping sick visitors away. Good hygiene lowers the number of germs that reach the child’s body, so even though their immune system is weak, they are exposed to fewer threats. This reduces hospital admissions, severe infections, and antibiotic use. Hand hygiene also protects other vulnerable patients in clinics and hospitals.[4][5]

2. Protective home environment and crowd avoidance

Children with ORAI1-related immunodeficiency often need a “protective environment.” Families try to avoid large crowds, day-care centres with frequent viral outbreaks, and people with obvious infections. Some children may need reduced exposure during peak viral seasons (such as RSV or flu season). This does not mean total isolation, but careful planning of visits, travel, and school attendance. Reducing exposure to infected individuals directly lowers the chance of life-threatening infections.[4][5]

3. Vaccination of household contacts (cocooning)

The affected child cannot safely receive many live vaccines, but people around them usually can. So parents, siblings, and caregivers should be fully vaccinated with inactivated vaccines (influenza, COVID-19, pertussis boosters, etc.). This “cocooning” strategy turns family members into a protective shield, so the child is less likely to come into contact with serious vaccine-preventable infections. The immunology team advises which live vaccines are safe for contacts and which should be timed carefully.[4]

4. Avoidance of live vaccines in the patient

Because T-cell function is severely impaired, live attenuated vaccines (such as live polio, MMR, varicella, BCG, or oral typhoid) can actually cause disease in these children. A key non-pharmacological “treatment” is simply not giving them these vaccines. Instead, they receive inactivated or subunit vaccines when and if the immunology team judges the benefit to outweigh the risk. This strategy is part of standard management for many severe combined immunodeficiencies.[4]

5. Regular specialist follow-up in an immunology centre

Care for ORAI1 deficiency should ideally be coordinated in a centre with experience in primary immunodeficiency and stem cell transplantation. Regular visits allow early detection of infections, monitoring of growth, lung function, and autoimmunity, and timely planning for HSCT. Multidisciplinary clinics (immunologists, infectious-disease specialists, neurologists, dentists, and physiotherapists) help manage the multi-system nature of the disease.[1][4][5]

6. Individual emergency and fever action plans

Families receive a written plan describing what to do if the child develops fever, cough, breathing difficulty, or unusual rashes. The plan usually includes a low threshold for going to hospital and guidance for emergency doctors (for example, “treat as sepsis in an immunocompromised child”). This plan saves time in emergencies, reduces delays to antibiotics, and improves survival from severe infections.[4]

7. Respiratory physiotherapy and airway clearance

Recurrent chest infections can leave behind mucus plugs and structural lung damage (bronchiectasis). Respiratory physiotherapists teach airway-clearance techniques, breathing exercises, and sometimes use devices that help move mucus out of the lungs. This decreases the amount of bacteria trapped in secretions and can reduce hospitalisations and long-term loss of lung function. For some children, this becomes a routine part of daily care, especially after HSCT.[1][4]

8. Heat and sun protection for anhidrosis

Because sweat glands do not work properly, children with ORAI1 deficiency and anhidrotic ectodermal dysplasia are at high risk for overheating. Non-drug treatment includes staying in cool rooms, avoiding direct midday sun, wearing light clothing, using fans, cooling vests, and frequent drinking of cool fluids. Parents learn to recognise early signs of heat stress, such as flushed skin, irritability, or fatigue, and respond quickly. These simple measures can prevent dangerous heat stroke.[2][6]

9. Intensive dental and oral care

Dental enamel defects are common, so early and regular dental care is essential. Dentists may apply fluoride varnish, sealants, or crowns to protect fragile teeth. Good brushing, flossing, and sometimes antimicrobial mouth rinses help prevent cavities and periodontal disease. This not only improves comfort and appearance but also lowers the risk of bacterial bloodstream infection originating from the mouth.[2]

10. Physiotherapy and occupational therapy for myopathy

Congenital myopathy causes low muscle tone and delayed motor milestones. Physiotherapists design exercises to strengthen muscles gradually, improve posture, and prevent contractures. Occupational therapists help with fine motor skills, daily tasks, and adaptations at home or school. These therapies do not correct the underlying calcium channel defect, but they maximise function, independence, and quality of life.[1][6]

11. Nutritional optimisation and safe food handling

Adequate energy, protein, and micronutrients support growth and immune function. Dietitians help families plan balanced meals and, when needed, high-calorie formulas or tube feeding. Safe food practices (washing hands, cooking meat thoroughly, avoiding raw eggs and unpasteurised milk) reduce exposure to food-borne pathogens. This is especially important when the child is neutropenic or post-transplant.[10]

12. School and learning support

Many children experience frequent hospital stays and fatigue. School support – such as home-based learning, flexible timetables, and infection-control policies in the classroom – helps them keep up with education while staying safe. Teachers and classmates can be educated about the condition in simple language to reduce stigma and encourage supportive behaviour.[5]

13. Psychological and family support

Living with a life-threatening rare disease is emotionally heavy for the child and the family. Psychologists, social workers, and patient organisations can offer counselling, coping strategies, and peer support. This support helps tackle anxiety, depression, caregiver burnout, and practical issues such as finances and transport to specialist centres.[5]

14. Genetic counselling for the family

ORAI1 deficiency is autosomal recessive, meaning both parents usually carry one changed gene. Genetic counselling explains inheritance, recurrence risk in future pregnancies, options for prenatal or preimplantation diagnosis, and the importance of testing siblings. Understanding the genetics helps families make informed reproductive choices and can lead to early diagnosis in affected relatives.[5][7]

15. Screening and early diagnosis of siblings

Early genetic and immunologic testing of newborn siblings allows prompt introduction of infection-prevention measures and planning for HSCT before severe infections occur. In some settings, newborn screening for severe combined immunodeficiency can also pick up severe T-cell defects early. Earlier diagnosis is strongly linked to better transplant outcomes.[4][7

16. Environmental control (smoke, mould, pollutants)

Second-hand smoke, indoor mould, and heavy air pollution damage the lungs of any child, but the risk is much higher in severe immunodeficiency. Families are advised to keep the home smoke-free, reduce dampness and mould, and avoid high-pollution areas when possible. This reduces baseline airway inflammation and may lower the risk and severity of respiratory infections.[4]

17. Use of irradiated, CMV-negative blood products

If transfusions are needed, guidelines recommend only irradiated, CMV-negative blood products in severe T-cell immunodeficiency. Irradiation prevents transfusion-associated graft-versus-host disease, and CMV-negative products reduce the chance of life-threatening viral transmission. This is a crucial “non-drug” safety measure whenever blood products are used.[4]

18. Non-invasive ventilation and sleep support in severe myopathy

Weak respiratory muscles can cause shallow breathing during sleep and retention of carbon dioxide. Sleep studies may show the need for non-invasive ventilation (such as BiPAP) at night. This support improves sleep quality, energy levels, and long-term heart and lung health. It is part of standard care for many congenital myopathies and can be adapted for ORAI1 deficiency.[6]

19. Rehabilitation after hematopoietic stem cell transplantation

After HSCT, children often need intensive rehabilitation: physiotherapy, occupational therapy, nutritional support, and psychological care. Even if immunity improves, myopathy and ectodermal features usually remain, so rehabilitation focuses on regaining strength, function, and participation in everyday life. Early rehabilitation is associated with faster recovery and better long-term outcomes.[4][5]

20. Participation in registries and research

Because ORAI1 deficiency is ultra-rare, participation in patient registries and carefully designed research studies helps doctors learn which treatments work best. This is not a treatment in itself, but it can indirectly improve future care and may provide access to new diagnostic tools or therapies such as gene-targeted approaches. Families should only join studies approved by ethical committees and discussed with their care team.[3][5]

---

Drug treatments

Safety reminder: Drug names below are for general educational content. Doses and schedules must always be set by the child’s own specialist team. Never start, stop, or change any medicine based on a web article.

1. Intravenous immunoglobulin (IVIG) replacement

IVIG is a pooled antibody product from healthy donors, given by intravenous infusion every 3–4 weeks. It replaces missing or poorly functioning antibodies and improves protection against many bacterial and some viral infections. IVIG is widely used for primary antibody deficiencies and is recommended for ORAI1-related combined immunodeficiency as part of baseline therapy. Side effects can include headache, chills, infusion reactions, and rarely kidney or clotting problems.[4][8]

2. Subcutaneous immunoglobulin (SCIG)

SCIG delivers similar immunoglobulin through small needles under the skin, usually weekly. It allows home-based treatment, more stable blood levels of IgG, and sometimes fewer systemic reactions. This can improve quality of life for families who live far from hospitals. Local redness or swelling at the infusion site is common but usually mild. The choice between IVIG and SCIG depends on age, venous access, lifestyle, and local expertise.[4][8]

3. Trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis

TMP-SMX is a combination antibiotic often used as low-dose daily or alternate-day prophylaxis against Pneumocystis jirovecii pneumonia and some bacterial infections in severe immunodeficiency. It is recommended in many guidelines for CRAC channelopathy and related combined immunodeficiencies. Typical side effects include rash, stomach upset, and, rarely, bone-marrow suppression or severe allergic reactions. Dosing is weight-based and carefully monitored.[4][9]

4. Alternative Pneumocystis prophylaxis (e.g., atovaquone)

If a child cannot tolerate TMP-SMX due to allergy or low blood counts, alternatives such as atovaquone or dapsone may be used under specialist supervision. These medicines provide protection against Pneumocystis pneumonia but have different side-effect profiles and sometimes higher cost. They must be dosed accurately and monitored for liver function, blood counts, and, in the case of dapsone, risk of haemolysis in G6PD deficiency.[4]

5. Broad-spectrum intravenous antibiotics for sepsis

When a child with ORAI1 deficiency develops fever or signs of sepsis, doctors rapidly start broad-spectrum IV antibiotics such as third- or fourth-generation cephalosporins or piperacillin-tazobactam, sometimes combined with aminoglycosides or vancomycin. These medicines aim to cover likely bacterial pathogens while cultures are pending. Dosing and choice depend on local resistance patterns, kidney function, and clinical severity. Close monitoring is needed to adjust treatment once culture results are available.[4][5]

6. Antifungal prophylaxis (e.g., fluconazole)

Children with severe combined immunodeficiency are at risk of invasive fungal infections, especially when neutrophil counts are low or they have central venous lines. Fluconazole or similar agents may be used as prophylaxis in selected cases, particularly around HSCT. Side effects include liver enzyme elevation and drug–drug interactions, so liver function tests and medication lists must be regularly reviewed.[4][10]

7. Antifungal treatment (e.g., echinocandins, amphotericin B)

For proven or strongly suspected invasive fungal infections, more potent agents such as echinocandins (micafungin, caspofungin) or amphotericin B may be used. These drugs are given intravenously in hospital and require monitoring of kidney function, liver function, and electrolyte levels. They are life-saving but can cause significant toxicities, so careful balancing of risks and benefits is needed.[4]

8. Antiviral prophylaxis against herpesviruses (e.g., acyclovir)

Herpesviruses such as HSV and VZV can cause severe disease in immunodeficient patients. Acyclovir or valacyclovir may be prescribed as prophylaxis around HSCT or during periods of intense immunosuppression. They inhibit viral DNA replication and are generally well tolerated but require dose adjustment in kidney disease. Common side effects include nausea and headache, with rare neurotoxicity at high levels.[4][15]

9. Antiviral therapy for CMV and related viruses (e.g., ganciclovir, valganciclovir)

Cytomegalovirus (CMV) reactivation is a major threat after stem cell transplantation. Drugs such as ganciclovir or valganciclovir are used for treatment or pre-emptive therapy based on viral load monitoring. They can suppress bone-marrow function and cause neutropenia, so full blood counts must be checked frequently. In ORAI1 deficiency, these medicines are used following general transplant and immunodeficiency protocols rather than disease-specific trials.[4]

10. RSV prophylaxis with monoclonal antibodies (e.g., palivizumab)

Infants with profound immunodeficiency are at high risk of severe respiratory syncytial virus (RSV) infection. Palivizumab is a monoclonal antibody given as monthly intramuscular injections during RSV season to reduce hospitalisations from RSV. Many national and international guidelines list severe immunodeficiency as a risk group where prophylaxis may be considered. Side effects are usually mild (fever, rash), but the cost is high.[9]

11. Corticosteroids for autoimmune complications

Some patients with CRAC channelopathy develop autoimmune problems such as autoimmune cytopenias. Short-term courses of corticosteroids (for example, prednisolone) may be used to control inflammation and raise blood counts. However, steroids also suppress immunity further, increase infection risk, affect growth, and cause metabolic side effects, so they must be used at the lowest effective dose and tapered under close supervision.[3][4]

12. Rituximab for refractory autoimmune cytopenias

Rituximab is a monoclonal antibody that depletes B cells by targeting CD20. It is sometimes used in difficult autoimmune cytopenias in primary immunodeficiency. By removing antibody-producing B cells, it can improve platelet or red cell counts, but it further weakens humoral immunity and may reactivate hepatitis B or other infections. Careful screening and long-term follow-up are needed.[3]

13. Granulocyte colony-stimulating factor (G-CSF, e.g., filgrastim)

Filgrastim is a G-CSF analogue that stimulates the bone marrow to produce more neutrophils. It is approved to reduce the incidence of infection in patients with severe chronic neutropenia or chemotherapy-induced neutropenia and is sometimes used in immunodeficiency and post-transplant settings. Side effects include bone pain, spleen enlargement, and very rarely splenic rupture. Dosing is weight-based and adjusted according to neutrophil counts.[13]

14. GM-CSF (sargramostim) to support myeloid recovery

Sargramostim is a GM-CSF analogue that promotes survival, proliferation, and differentiation of myeloid progenitors. It is approved for acceleration of myeloid reconstitution after bone-marrow or peripheral blood stem cell transplantation and for certain chemotherapy settings. In the context of HSCT for ORAI1 deficiency, GM-CSF can help white blood cells recover faster. Common side effects include fever, injection-site reactions, and fluid retention.[14]

15. Thrombopoietin receptor agonists (eltrombopag, romiplostim) in severe thrombocytopenia

Some patients with primary immunodeficiency develop severe, treatment-refractory immune thrombocytopenia. Thrombopoietin receptor agonists such as eltrombopag or romiplostim can raise platelet counts by stimulating platelet production. They are approved for chronic ITP and have also been used in aplastic anaemia. Risks include liver enzyme elevation and increased risk of clotting events, so regular monitoring is essential.[15][16]

[15]

16. Broad-spectrum empiric antibiotics for febrile neutropenia

When neutrophil counts are low and the child has a fever, immediate empiric IV antibiotics according to febrile-neutropenia protocols are crucial. The exact regimen varies by hospital but often includes an antipseudomonal beta-lactam, with or without additional agents. This approach has strong evidence for reducing mortality in high-risk neutropenic patients, and the same principles apply to children with ORAI1-related combined immunodeficiency.[4]

17. Antituberculous treatment where indicated

In regions where tuberculosis is common, children with severe immunodeficiency may develop severe TB or opportunistic mycobacterial infections. Standard multi-drug regimens (isoniazid, rifampicin, pyrazinamide, ethambutol and others) are used following national TB guidelines, sometimes with longer durations. Close monitoring for drug toxicity and interactions with other medicines (especially post-transplant) is needed.[4]

18. Immunosuppressive therapy after HSCT

After HSCT, drugs such as calcineurin inhibitors (cyclosporine, tacrolimus), methotrexate, or mycophenolate are used to prevent or treat graft-versus-host disease (GVHD). These medicines intentionally damp down the new immune system while it is engrafting. They can increase infection risk and cause kidney, liver, or blood pressure side effects, so transplant teams adjust doses very carefully.[4][5]

19. Antiemetics, pain relief, and supportive drugs

Although not specific to ORAI1 deficiency, supportive medicines such as antiemetics (for nausea), proton-pump inhibitors (for gastric protection), and carefully chosen analgesics are essential during intensive treatments like HSCT. They help children tolerate therapy, maintain nutrition, and stay comfortable, which indirectly supports immune recovery and overall outcomes.[5]

20. Experimental or targeted therapies (future directions)

Research into small-molecule modulators of CRAC channels is ongoing, mostly in autoimmune and inflammatory diseases. For ORAI1 loss-of-function, the main curative strategy remains HSCT or future gene-based approaches rather than channel inhibitors. However, basic research into CRAC channel pharmacology improves understanding of disease mechanisms and may eventually guide new therapies.[3]

---

Dietary molecular supplements

Important: Supplements cannot repair the ORAI1 gene or replace HSCT. They may support general health when used under medical supervision but are not stand-alone treatments.

1. Vitamin D – Vitamin D helps regulate both innate and adaptive immunity and supports bone health. Deficiency is common in chronically ill or indoor children. Correcting low vitamin D can modestly improve infection outcomes and bone strength, but very high doses can cause toxicity (high calcium, kidney problems). Dosing must be checked with blood tests and guided by a clinician.[10]

2. Zinc – Zinc is crucial for normal function of many enzymes and immune cells. Mild zinc deficiency can increase infection risk, and supplementation may improve growth and immune responses where deficiency exists. However, taking too much zinc can upset copper balance and cause gastrointestinal symptoms, so doses should respect age-appropriate limits.[10]

3. Selenium – Selenium is part of antioxidant enzymes that protect cells from oxidative damage during infection and inflammation. Low selenium status has been associated with worse outcomes in some infections. Carefully dosed supplementation in deficient individuals may support immune function, but excess intake can cause hair loss, nail changes, and nerve problems.[10]

4. Vitamin C – Vitamin C acts as an antioxidant and supports neutrophil function and collagen synthesis. Regular intake in recommended dietary amounts from food or supplements can modestly reduce the duration of common cold symptoms in some groups. Extremely high doses may cause stomach upset and increase kidney stone risk.[10]

5. Vitamin A – Vitamin A is important for mucosal immunity and epithelial integrity in the gut and lungs. In vitamin A deficiency, supplementation reduces infection severity, but excessive amounts are toxic (liver damage, bone pain, raised intracranial pressure). For children with chronic disease, vitamin A status should be checked before any high-dose supplementation.[10]

6. Omega-3 fatty acids – Omega-3 fats from fish oil or plant sources may modulate inflammation and support cardiovascular health. In some studies of surgical and critically ill patients, “immunonutrition” formulas containing omega-3s, arginine, and nucleotides reduced postoperative infections, although benefits are not universal. For ORAI1 deficiency, balanced omega-3 intake is mainly supportive, not curative.[10]

7. Glutamine – Glutamine is a conditionally essential amino acid used by rapidly dividing cells, including immune cells and enterocytes. Certain clinical trials suggest that glutamine-containing immunonutrition may reduce infections in surgical or ICU populations, but results in general paediatric practice are mixed. In ORAI1 deficiency, glutamine may be considered as part of dietician-supervised feeding plans, not as a stand-alone immunity cure.[10]

8. Probiotics – Specific probiotic strains have shown modest benefits in reducing the duration or frequency of some respiratory infections in children. However, in severely immunocompromised patients, there is a theoretical risk of probiotic-related sepsis, so use must be discussed with the specialist team. If used, clinicians choose well-studied strains and monitor closely.[10]

9. Multivitamin–mineral combinations – In children with poor diet or chronic illness, a standard paediatric multivitamin–mineral supplement can help cover common gaps (B vitamins, iron, trace elements). Some trials suggest improved growth or immune markers with such supplements, but they are not disease-specific therapies. Over-supplementation beyond recommended daily amounts should be avoided.[10]

10. Medical nutrition formulas (“immunonutrition”) – Special enteral formulas enriched with arginine, omega-3 fatty acids, nucleotides, or antioxidants have been studied in surgical and critically ill patients. Some meta-analyses show reduced infection rates, though not always better survival. In ORAI1 deficiency, such formulas may occasionally be used in hospital under dietician guidance, especially around major surgery or HSCT.[10]

---

Immunity-booster / regenerative / stem-cell-related drugs

1. Filgrastim (G-CSF) – Stimulates neutrophil production and is approved to reduce infection in severe chronic neutropenia and chemotherapy-induced neutropenia. In ORAI1 deficiency, it may be used when neutrophil counts are low, especially around HSCT. It does not correct the T-cell signalling defect but can reduce bacterial infection risk linked to neutropenia.[13]

2. Sargramostim (GM-CSF) – Encourages broader myeloid recovery, including monocytes and granulocytes, mainly after HSCT or high-dose chemotherapy. Faster white-cell recovery can shorten hospital stay and reduce time at risk for life-threatening infections. Careful dosing and monitoring are required to avoid excessive inflammation or fluid retention.[14]

3. Thrombopoietin receptor agonists (eltrombopag, romiplostim) – These medicines stimulate platelet production and are used for chronic immune thrombocytopenia or severe aplastic anaemia. In primary immunodeficiency, they may be considered when autoimmune thrombocytopenia is resistant to steroids and IVIG. They can be thought of as “regenerative” for platelet counts but need close monitoring for liver toxicity and thrombosis.[15][16]

4. High-dose IVIG as immunomodulation – At higher doses than those used for replacement, IVIG can modulate autoantibodies and immune signalling pathways. This is sometimes used for autoimmune cytopenias or inflammatory complications in primary immunodeficiency. It does not fix the ORAI1 defect but can control damaging autoimmunity while preparations for HSCT continue.[3][4]

5. Hematopoietic stem cell graft (HSCT cell product) – Technically this is a cell therapy rather than a drug, but the infused stem-cell product behaves like a “living medicine” that rebuilds the immune system. Donor stem cells engraft in the bone marrow and give rise to functional T and B cells that have normal ORAI1 channels. HSCT is currently the only established curative approach for the immune defect in ORAI1 deficiency, although it does not correct myopathy or ectodermal dysplasia.[4][5]

6. Emerging gene-targeted therapies (research) – In future, gene editing or gene addition strategies for CRAC channelopathies may allow correction of the ORAI1 gene in the patient’s own stem cells, similar to gene therapy approaches already used for other forms of severe combined immunodeficiency. At present, these approaches remain experimental and are not standard care, but they represent a truly regenerative concept.[3]

---

Surgical and interventional procedures

1. Hematopoietic stem cell transplantation (HSCT) – The central “curative-intent” intervention involves conditioning chemotherapy followed by infusion of donor bone-marrow, peripheral-blood, or cord-blood stem cells. HSCT aims to replace the defective immune system with a new one that can respond normally to infections. It is complex and risky but offers the best long-term survival for many children with severe combined immunodeficiency, including ORAI1 deficiency.[4][5]

2. Central venous catheter insertion – Many children require long-term central lines (such as tunneled catheters or ports) for IVIG, antibiotics, and HSCT chemotherapy. This surgical procedure provides reliable venous access, reducing repeated needle sticks and allowing safe delivery of life-saving treatments. However, it also carries risk of infections and thrombosis, so strict line-care protocols are essential.[4]

3. Gastrostomy tube placement – Some children with severe myopathy and feeding difficulties benefit from a gastrostomy tube (PEG) for reliable nutrition and medicine delivery. The procedure involves placing a tube directly into the stomach through the abdominal wall. It supports adequate growth and medication delivery when oral feeding is not enough and can reduce the risk of aspiration from prolonged mealtimes.[6]

4. Dental restorative procedures – Because tooth enamel is fragile, children may need crowns, caps, or other restorative dental procedures under local or general anaesthesia. These interventions protect teeth from fracture, reduce pain, and improve chewing and nutrition. Proper dental restoration also decreases chronic oral infection, which can otherwise seed serious systemic infections.[2]

5. Diagnostic lung or lymph-node biopsies – In complicated cases with unclear infections, malignancy suspicion, or interstitial lung disease, a biopsy may be required. While not specific to ORAI1 deficiency, such procedures help clarify the diagnosis and guide targeted treatment. Because of the high infection risk, these interventions are only done when essential and in experienced centres.[4][5]

---

Prevention tips

1. Early diagnosis in at-risk families – Testing siblings and using genetic counselling to identify affected infants early allows prompt infection prevention and HSCT planning.[5][7]

2. Up-to-date vaccination of household members – Ensure everyone around the child receives their recommended inactivated vaccines, including flu and COVID-19 boosters.[4]

3. Avoid live vaccines in the patient – Prevent vaccine-derived infections by strictly avoiding live vaccines unless an immunologist specifically clears them.[4]

4. Prompt treatment of any fever – Teach families that fever in a child with severe immunodeficiency is an emergency that needs same-day medical assessment.[4]

5. Good daily hygiene at home – Regular handwashing, surface cleaning, and safe food handling reduce everyday infection risks.[4]

6. Smoke-free and low-mould home environment – Avoiding tobacco smoke and indoor dampness protects vulnerable lungs.[4]

7. Regular dental and eye checks – Routine dental visits and vision checks reduce complications of ectodermal dysplasia and myopathy.[2][6]

8. Healthy weight and nutrition – Balanced, safe nutrition supports better outcomes from infections and major procedures like HSCT.[10]

9. Consistent follow-up with specialists – Keeping regular appointments allows minor issues to be treated before they become emergencies.[5]

10. Emergency information card – Carry a simple card or letter explaining the diagnosis, infection risk, and need for urgent antibiotics in case of illness. This helps emergency staff act quickly.[4]

(All paragraphs above reference sources [1]–[10] as already listed.)

---

When to see a doctor urgently

Parents or caregivers should seek urgent medical care immediately (same day, emergency department if needed) if a child with ORAI1-related immunodeficiency has:

• Fever (often defined by the care team, for example ≥38.0°C), especially if lasting more than a few hours or associated with chills.[4]

• Rapid or difficult breathing, persistent cough, grunting, or chest pain.

• Poor feeding, vomiting, or diarrhoea that leads to dehydration (dry mouth, no tears, reduced urine).

• Extreme tiredness, confusion, floppy muscles, or sudden change in behaviour.

• Any new rash, especially with fever or blisters.

• Bleeding, easy bruising, or very pale skin.

• Signs of heat stress such as flushed, hot skin, irritability, or collapse, especially in hot weather due to anhidrosis.[2][4][6]

For non-urgent issues like feeding difficulties, slow growth, chronic constipation, or school problems, parents should still contact the specialist team promptly but can usually schedule a clinic visit rather than going to the emergency room.

---

What to eat and what to avoid

1. Eat: Well-cooked lean proteins (chicken, fish, eggs cooked through, lentils) to support muscle and immune-cell repair.

2. Eat: A variety of fruits and vegetables (washed and, in high-risk periods, often peeled or cooked) to provide vitamins and antioxidants.

3. Eat: Whole grains and healthy fats (olive oil, small amounts of nuts if safe for age) for energy and overall health.

4. Eat: Adequate dairy or calcium-fortified alternatives for bone strength, unless the child is lactose intolerant.

5. Avoid: Raw or undercooked meat, fish, or eggs, which may carry dangerous bacteria or parasites.

6. Avoid: Unpasteurised milk, cheeses made from unpasteurised milk, and unpasteurised juices.

7. Avoid: Buffet-style foods or salad bars where food sits at room temperature, as germs can grow quickly.

8. Avoid: Very high doses of supplements or herbal products without the doctor’s approval, as they may interact with medicines or be unsafe.

9. Avoid: Sugary drinks and ultra-processed snacks in large amounts, which can displace more nutritious foods.

10. General rule: Any major diet changes or special “immune-boosting” products should be discussed with the immunology or dietitian team first.

These points are based on general “neutropenic” or immunocompromised-diet advice used for cancer and HSCT patients.[10]

---

Frequently asked questions

1. Is combined immunodeficiency due to ORAI1 deficiency the same as classic SCID?

It is related but not identical. In ORAI1 deficiency, T and B cells are usually present in normal numbers but cannot function properly because they lack store-operated calcium entry. This leads to combined immunodeficiency with severe infections, similar to many forms of severe combined immunodeficiency (SCID), but with additional features such as myopathy and ectodermal dysplasia.[1][3]

2. How is ORAI1 deficiency diagnosed?

Doctors suspect the diagnosis in children with early-onset severe infections, muscle weakness, and ectodermal features like enamel defects and inability to sweat. Blood tests show abnormal T-cell activation and almost absent store-operated calcium entry. Genetic testing then identifies pathogenic variants in the ORAI1 gene, confirming the diagnosis.[1][5][7]

3. Can this condition be cured?

The immune defect can often be effectively corrected by hematopoietic stem cell transplantation, which replaces the faulty immune system. However, HSCT does not usually fix the muscle weakness or ectodermal features. Research into gene-based therapies may offer new options in the future.[4][5]

4. Will every child with ORAI1 deficiency need HSCT?

Most published cases describe very severe disease with high early-life mortality without HSCT, so transplantation is strongly considered for many children. The exact timing and decision depend on infection history, donor availability, and the child’s overall health. This decision is always made by an experienced transplant and immunology team in partnership with the family.[4][6]

5. Does ORAI1 deficiency affect the brain or intelligence?

Most reports focus on immunity, muscles, and ectodermal structures. Some children may have developmental delay or learning difficulties related to chronic illness, hospitalisations, or complications like severe infections, but there is no single, clear cognitive pattern. Early supportive therapies and good disease control help children reach their best potential.[1][6]

6. Can adults have undiagnosed ORAI1 deficiency?

Because the disease is usually very severe in early life, most untreated patients become critically ill in infancy or early childhood. Adult diagnosis would be extremely unusual and would likely represent a milder or mixed-function variant. However, as genetic testing becomes more common, milder cases may be identified in older individuals.[6][22]

7. Is ORAI1 deficiency inherited?

Yes. It is usually inherited in an autosomal recessive pattern. This means that both parents carry one non-working copy of ORAI1, but are typically healthy. When two carriers have a child, there is a 25% chance the child will have the condition, a 50% chance of being a carrier, and a 25% chance of inheriting two working copies.[5][7]

8. Can this condition be detected during pregnancy?

If the exact ORAI1 variants in a family are known, prenatal diagnosis (for example, by chorionic villus sampling or amniocentesis) or preimplantation genetic testing can sometimes be offered. These options require careful counselling to discuss benefits, risks, and ethical questions, and availability varies by country.[5]

9. Why do children with ORAI1 deficiency have muscle weakness?

The same CRAC calcium channels that are essential for T-cell activation also play roles in muscle cells. When ORAI1 is not working, calcium signalling in muscle fibres is impaired, leading to congenital myopathy, hypotonia, and delayed motor milestones. This explains why ORAI1 deficiency affects both the immune system and skeletal muscles.[1][6][23]

10. What is ectodermal dysplasia in this context?

Ectodermal dysplasia refers to abnormal development of structures derived from the embryonic ectoderm, such as teeth, hair, nails, and sweat glands. In ORAI1 deficiency, patients often have poor enamel, abnormal or missing teeth, and an inability to sweat (anhidrosis). This combination of immune deficiency and ectodermal dysplasia represents a unique form of “CRAC channelopathy.”[2][31]

11. Are there lifestyle changes that can “boost” the immune system in ORAI1 deficiency?

Healthy sleep, nutrition, and hygiene are always important, but they cannot repair the underlying calcium channel defect. Supportive measures and supplements only work alongside medical treatments such as immunoglobulin replacement, prophylactic antibiotics, and HSCT. Claims that diet alone can cure this condition are misleading and potentially dangerous.[4][10]

12. Can children with ORAI1 deficiency attend school?

Many children can attend school with proper infection-control measures, vaccination of classmates, and flexibility during outbreaks or treatment periods. Plans may include mask use during high-risk seasons, reduced class sizes, or blended learning with at-home options. Decisions are personalised based on the child’s immune status and the advice of their care team.[4][5]

13. What is the long-term outlook (prognosis)?

Without treatment, the prognosis is poor because of recurrent life-threatening infections. With timely diagnosis, immunoglobulin replacement, infection prophylaxis, and HSCT, survival and quality of life can improve considerably. However, myopathy and ectodermal problems often persist and may need lifelong supportive care.[1][4][6]

14. Can ORAI1 deficiency lead to cancer?

Severe, chronic immune deficiency in general increases the risk of certain cancers, especially virus-associated lymphomas, because the immune system cannot adequately control oncogenic viruses or remove abnormal cells. A few patients with CRAC channelopathy and related defects have developed virus-associated tumours, but the total number of reported ORAI1 cases is still small.[15][23]

15. Where can families find more support and information?

Families are often referred to national or international primary-immunodeficiency patient organisations, rare-disease networks, and online resources curated by expert groups. These groups provide patient-friendly explanations, connect families with others facing similar challenges, and sometimes offer help with travel, accommodation, and advocacy for specialised care.[5][7]

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: February 13, 2025.